In oncology, the scalpel is only as precise as the vision behind it. Surgeons battling tumors buried in complex organs often rely on static images and instinct, a dangerous mix when millimeters can decide survival. That blind spot, between what you see and what you need to see, has fueled repeat surgeries, spiraling costs, and outcomes no one should accept. Method AI, a Boston spin-out from Cleveland Clinic, was built to close that gap with a platform that doesn’t just track the surgery, it rewrites the visibility inside it.
The breakthrough is elegant in its brutality. Continuous 3D ultrasound flows into AI-generated surgical plans that update in real time. Surgeons gain a subsurface map that moves as the procedure unfolds, revealing anatomy traditional cameras cannot. For oncology, where “clean margins” are the line between remission and relapse, that means precision no human eye could deliver unaided. If you’ve ever wished for X-ray vision in an OR, Method AI is about as close as the laws of physics currently allow.
Method AI was founded in 2021 to answer a single recurring complaint from robotics surgeons: how do we know we’ve removed it all? Doug Teany, Co-Founder and Chief Executive Officer, had the experience to answer. At Corindus Vascular Robotics, he oversaw the world’s first remote robotic heart procedure in 2018 and the first robotic neurovascular intervention in 2019. Before that, he spent more than seven years at Boston Scientific and served as an Engineer in the U.S. Army Reserves. With dual degrees from Purdue, Doug Teany is no stranger to turning technical breakthroughs into medical milestones.
Investors have noticed. Method AI just secured a $20 million Series A, led by a private family office with Cleveland Clinic and JobsOhio Growth Capital Fund doubling down. This isn’t fast money chasing a buzzword; it’s seasoned capital betting on real clinical traction. From a 5-person founding team to about 25 employees by mid-2025, the company has already launched pilots at Cleveland Clinic and a major Boston hospital.
The trajectory is set. FDA IDE submission is planned for late 2025, with European trials in 2026 and commercial launch in 2027. A preclinical validation already showed a 25% improvement in margin clearance in swine models, a number that translates to fewer failed surgeries and system-wide savings worth hundreds of millions. With over 5,000 robotic oncology suites in the U.S. and Europe representing a $500 million annual device opportunity, the market is primed.
Method AI is not selling miracles. It is selling clarity in a field where surgeons have been flying half-blind for decades. That clarity is survival, cost savings, and a future where the phrase “we think we got it all” can finally be backed by evidence. Congratulations to Doug Teany and the Method AI team for raising the $20 million Series A and for pushing surgical oncology toward a sharper, smarter tomorrow.
